-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drugs In Development, 2023’, provides an overview of the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Peanut Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘Peanut Allergy - Drugs In Development, 2023’, provides an overview of the Peanut Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peanut Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Food Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘Food Allergy - Drugs In Development, 2023’, provides an overview of the Food Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Food Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DS-1103 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DS-1103 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DS-1103 in Non-Small Cell Lung Cancer Drug Details: DS-1103...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Non-Disclosed in Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Non-Disclosed in Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Non-Disclosed in Diabetes Drug Details:Drug is under development for the treatment of diabetes. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNP-201 in Peanut Allergy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CNP-201 in Peanut Allergy Drug Details:CNP-201 is under development for the treatment of peanut allergy. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-0036 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HB-0036 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HB-0036 in Gastric Cancer Drug Details:HB-0036 a bi-specific antibody is under development for...